OncoVerity

Aurora, United States

OncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.

$14.0M raised

Nov 2024

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has OncoVerity raised?

OncoVerity has raised $14.0M in total funding. The most recent round was Series A. The last funding was announced in November 2024.

Who are OncoVerity's investors?

OncoVerity's investors include argenx, RefinedScience, University License Equity Holdings.

Where is OncoVerity headquartered?

OncoVerity is headquartered in Aurora, United States.

What does OncoVerity do?

OncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.

What stage is OncoVerity at?

OncoVerity is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 21, 2024.

MLA

"OncoVerity — Funding & Investors." VCBacked, November 21, 2024, https://www.vcbacked.co/company/oncoverity. Accessed July 2, 2026.

APA

VCBacked. (2024). OncoVerity — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/oncoverity

Wikipedia (cite web)

{{cite web |title=OncoVerity — Funding & Investors |url=https://www.vcbacked.co/company/oncoverity |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 21, 2024.